Literature DB >> 8662504

Mechanism of suppression of cell-mediated immunity by measles virus.

C L Karp1, M Wysocka, L M Wahl, J M Ahearn, P J Cuomo, B Sherry, G Trinchieri, D E Griffin.   

Abstract

The mechanisms underlying the profound suppression of cell-mediated immunity (CMI) accompanying measles are unclear. Interleukin-12 (IL-12), derived principally from monocytes and macrophages, is critical for the generation of CMI. Measles virus (MV) infection of primary human monocytes specifically down-regulated IL-12 production. Cross-linking of CD46, a complement regulatory protein that is the cellular receptor for MV, with antibody or with the complement activation product C3b similarly inhibited monocyte IL-12 production, providing a plausible mechanism for MV-induced immunosuppression. CD46 provides a regulatory link between the complement system and cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662504     DOI: 10.1126/science.273.5272.228

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  134 in total

1.  Human major group rhinoviruses downmodulate the accessory function of monocytes by inducing IL-10.

Authors:  J Stöckl; H Vetr; O Majdic; G Zlabinger; E Kuechler; W Knapp
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

2.  Inhibition of in vitro leukocyte proliferation by morbilliviruses.

Authors:  J Heaney; T Barrett; S L Cosby
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.

Authors:  E C Hsu; R E Dörig; F Sarangi; A Marcil; C Iorio; C D Richardson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  Cofactors that may influence vaccine responses.

Authors:  Guy de Bruyn
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.

Authors:  Sompong Vongpunsawad; Numan Oezgun; Werner Braun; Roberto Cattaneo
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

6.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells.

Authors:  Jeong-Hyeon Sohn; Puran S Bora; Hye-Jung Suk; Hector Molina; Henry J Kaplan; Nalini S Bora
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

7.  Measles virus (MV) nucleoprotein binds to a novel cell surface receptor distinct from FcgammaRII via its C-terminal domain: role in MV-induced immunosuppression.

Authors:  David Laine; Marie-Claude Trescol-Biémont; Sonia Longhi; Geneviève Libeau; Julien C Marie; Pierre-Olivier Vidalain; Olga Azocar; Adama Diallo; Bruno Canard; Chantal Rabourdin-Combe; Hélène Valentin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients.

Authors:  Vuslat Yilmaz; Veysi Demirbilek; Candan Gürses; Sibel P Yentür; Serap Uysal; Zuhal Yapici; Gülden Yilmaz; Aaron Muncey; Ozlem Cokar; Emel Onal; Aysen Gökyiğit; Güher Saruhan-Direskeneli
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

9.  Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein.

Authors:  Evelena Ontiveros; Taeg S Kim; Thomas M Gallagher; Stanley Perlman
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Authors:  Karen Bieback; Egil Lien; Ingo M Klagge; Elita Avota; Jürgen Schneider-Schaulies; W Paul Duprex; Herrmann Wagner; Carsten J Kirschning; Volker Ter Meulen; Sibylle Schneider-Schaulies
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.